Literature DB >> 28843324

Minimally Invasive Heart Valve Surgery.

Ismail Bouhout1, Marie-Catherine Morgant1, Denis Bouchard2.   

Abstract

Minimally invasive valve surgery represents a recent and significant advance in modern heart surgery. Indeed, many less invasive approaches for both the aortic and mitral valves have been developed in the past 2 decades. These procedures were hypothesized to result in less operative trauma, which might translate into better patient outcomes. However, this clinical benefit remains controversial in the literature. The aim of this review is to discuss the evidence surrounding minimally invasive heart valve surgery in the current era. A systematic search of the literature from 2006-2016 was performed looking for articles reporting early or late outcomes after minimally invasive valve surgery. Less invasive valve surgery is safe and provides long-term surgical outcomes similar to those of standard sternotomy. In addition, these approaches result in a reduction in overall hospital length of stay and may mitigate the risk of early morbidity-mainly postoperative bleeding, transfusions, and ventilation duration.
Copyright © 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28843324     DOI: 10.1016/j.cjca.2017.05.014

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  2 in total

Review 1.  Minimally invasive mitral valve repair.

Authors:  Mateo Marin Cuartas; Piroze Minoo Davierwala
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-07-27

2.  Interdisciplinary and cross-sectoral perioperative care model in cardiac surgery: implementation in the setting of minimally invasive heart valve surgery (INCREASE)-study protocol for a randomized controlled trial.

Authors:  Susanne G R Klotz; Gesche Ketels; Christian A Behrendt; Hans-Helmut König; Sebastian Kohlmann; Bernd Löwe; Johannes Petersen; Sina Stock; Eik Vettorazzi; Antonia Zapf; Inke Zastrow; Christian Zöllner; Hermann Reichenspurner; Evaldas Girdauskas
Journal:  Trials       Date:  2022-06-23       Impact factor: 2.728

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.